NewslettersMuscle Cell NewsFibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase III Clinical Study of Pamrevlumab in Duchenne Muscular DystrophyBy lbeveridge - June 20, 20220185FibroGen, Inc. announced completion of patient enrollment for LELANTOS-2, a Phase III clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy.[FibroGen, Inc.]Press Release